BRIEF published on 02/18/2026 at 07:35, 5 months ago GenSight Biologics Strengthens Regulatory Leadership with Key Appointments Gene Therapy Strategic Appointments GenSight Biologics Retinal Diseases Regulatory Leadership
PRESS RELEASE published on 02/18/2026 at 07:30, 5 months ago Inside Information / Other news releases GenSight Biologics strengthens Regulatory Affairs & Quality team with two key appointments to support global regulatory strategy and upcoming milestones in gene therapy for retinal diseases Quality Regulatory Affairs GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 02/10/2026 at 07:35, 5 months 8 days ago GenSight Biologics Begins REVISE Study for GS010 Therapy GenSight Biologics LHON REVISE Study GS010 Therapy 15-20 National Hospital
BRIEF published on 02/10/2026 at 07:35, 5 months 8 days ago First Steps of the REVISED Clinical Study on GS010/LUMEVOQ® Clinical Study Gene Therapy GenSight Biologics LUMEVOQ Optic Neuropathy
PRESS RELEASE published on 02/10/2026 at 07:30, 5 months 8 days ago Inside Information / Other news releases 15-20 National Hospital and GenSight Biologics treat first patient in GS010/LUMEVOQ® REVISE Study, for Leber Hereditary Optic Neuropathy. Clinical study supported by ANSM and aiming to enroll 14 patients in France GenSight Biologics LHON GS010/LUMEVOQ REVISE Study 15-20 National Hospital
BRIEF published on 01/29/2026 at 00:26, 5 months 20 days ago GenSight Biologics Reports EGM Results Shareholders Capital Increase Extraordinary General Meeting GenSight Biologics Financial Authorizations
PRESS RELEASE published on 01/29/2026 at 00:21, 5 months 20 days ago Inside Information / Other news releases GenSight Biologics announces successful Extraordinary General Meeting approving financial authorizations renewal and clarifying rejection of 8th resolution, enhancing company's strategic flexibility Strategy Extraordinary General Meeting GenSight Biologics Gene Therapies Financial Authorizations
BRIEF published on 12/29/2025 at 08:05, 6 months 20 days ago GenSight Biologics Completes €2.9 Million Fundraising Shareholders Fundraising Gene Therapy Retinal Diseases Compassionate Use
PRESS RELEASE published on 12/29/2025 at 08:00, 6 months 20 days ago Inside Information / Other news releases GenSight Biologics successfully raises nearly €2.9 million to fund gene therapies for retinal neurodegenerative diseases, plans to use proceeds for development and operational needs through 2026 Fundraising Proceeds GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 12/22/2025 at 07:05, 6 months 27 days ago Issuance of a compassionate access authorization for GS010/LUMEVOQ® Gene Therapy GenSight Biologics NOHL ANSM Compassionate Access
Published on 07/17/2026 at 15:00, 22 hours 18 minutes ago Four Nines Gold to Showcase Hayden Hill Opportunity to U.S. Investors at OTC Markets Virtual Investor Conference
Published on 07/17/2026 at 14:00, 23 hours 18 minutes ago Redwood AI Announces Pricing of $3.5 Million Private Placement
Published on 07/17/2026 at 13:00, 1 day ago Blue Lagoon Surpasses $10 Million In Revenue As Dome Mountain Production Rises To 125 Tonnes Per Day
Published on 07/17/2026 at 01:00, 1 day 12 hours ago RJK Explorations Ltd. Announces Closing of Private Placement for Gross Proceeds of $310,000
Published on 07/17/2026 at 00:00, 1 day 13 hours ago LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH (OH) to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity Pipeline
Published on 07/18/2026 at 08:00, 5 hours 18 minutes ago Northern Data AG – Changes to the Supervisory Board and the Management Board
Published on 07/17/2026 at 20:35, 16 hours 42 minutes ago Farizon Opens Global Spare Part Distribution Center to Strengthen International Aftersales Support
Published on 07/17/2026 at 18:55, 18 hours 22 minutes ago CGTN: China vows to make AI a driver for shared prosperity amid widening AI divide
Published on 07/17/2026 at 18:32, 18 hours 45 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 07/17/2026 at 18:31, 18 hours 46 minutes ago Disclosure of transactions in own shares from July 13 to July 17, 2026
Published on 07/17/2026 at 18:00, 19 hours 18 minutes ago Information regarding compliance with gender balance rules within the Board of Directors
Published on 07/17/2026 at 17:45, 19 hours 33 minutes ago Imerys-07-2026-information-share-capital-and-voting-rights-as-of-30-June-2026
Published on 07/16/2026 at 18:08, 1 day 19 hours ago Aéroports de Paris S.A - June and half-year 2026 traffic figures
